Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Health and Clinical Excellence (NICE). Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2005 Aug. 39 p. (Technology appraisal; no. 93).

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

  • Irinotecan and oxaliplatin, within their licensed indications, are recommended as treatment options for people with advanced colorectal cancer as follows:
    • Irinotecan in combination with 5-fluorouracil and folinic acid as first-line therapy, or irinotecan alone in subsequent therapy
    • Oxaliplatin in combination with 5-fluorouracil and folinic acid as first-line or subsequent therapy.
  • Raltitrexed is not recommended for the treatment of patients with advanced colorectal cancer. Its use for this patient group should be confined to appropriately designed clinical studies.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence supporting the recommendations is not specifically stated.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Health and Clinical Excellence (NICE). Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2005 Aug. 39 p. (Technology appraisal; no. 93).

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2005 Aug

GUIDELINE DEVELOPER(S)

National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]

SOURCE(S) OF FUNDING

National Institute for Health and Clinical Excellence (NICE)

GUIDELINE COMMITTEE

Appraisal Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee Members: Dr Darren Ashcroft, Senior Lecturer, School of Pharmacy and Pharmaceutical Sciences; Professor David Barnett, Professor of Clinical Pharmacology, University of Leicester; Mr Brian Buckley, Vice Chairman, InContact; Dr Mark Chakravarty, Head of Government Affairs and NHS Policy, Procter and Gamble Pharmaceuticals (UK); Ms Donna Covey, Chief Executive, National Asthma Campaign; Dr Mike Davies, Consultant Physician, University Department of Medicine and Metabolism, Manchester Royal Infirmary; Professor Jack Dowie, Health Economist, London School of Hygiene and Tropical Medicine; Dr Fergus Gleeson, Consultant Radiologist, The Churchill Hospital, Oxford; Ms Sally Gooch, Director of Nursing and Workforce Development, Mid Essex Hospital Services NHS Trust; Professor Peter Jones, Professor of Statistics and Dean, Faculty of Natural Sciences, Keele University; Ms Rachel Lewis, Staff Nurse (Nephrology), Hull Royal Infirmary; Professor Jonathan Michaels, Professor of Vascular Surgery, University of Sheffield; Dr Ruairidh Milne, Senior Lecturer in Public Health, National Coordinating Centre for Health Technology; Dr Neil Milner, General Practitioner, Sheffield; Mr Miles Scott, Chief Executive, Harrogate Health Care NHS Trust; Dr Ken Stein, Senior Lecturer, Peninsula Technology Assessment Group (PenTAG), University of Exeter; Professor Andrew Stevens (Chair) Professor of Public Health, University of Birmingham

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

Print copies: Available from the National Health Service (NHS) Response Line 0870 1555 455. ref: N0906. 11 Strand, London, WC2N 5HR.

PATIENT RESOURCES

The following is available:

  • Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Understanding NICE guidance – information for people with advanced colorectal cancer, their families and carers, and the public. London (UK): National Institute for Health and Clinical Excellence (NICE); 2005 Aug. 7 p. (Technology appraisal 93).

Electronic copies: Available in Portable Document Format (PDF) from the National Institute for Health and Clinical Excellence (NICE) Web site.

Print copies: Available from the NHS Response Line 0870 1555 455. ref: N0907. 11 Strand, London, WC2N 5HR.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo